Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Related Videos
Related Content